First half 2014: Strong sales and profit growth / guidance confirmed

August 29, 2014
Bachem building at the Bubendorf manufacturing site
Bubendorf/Basel, August 29, 2014 – Bachem Group (SIX: BANB) significantly improved its performance in terms of sales and profit during the first half of 2014 and confirmed its continuous growth expectations. Bachem increased its sales to 86.7 million CHF (+8.2% in local currency). Operating income advanced 28.8% to 16.4 million CHF. That figure includes a gain of 2.0 million CHF on the divestment of its immunology product line. The EBIT and net income margins rose to 18.9% and 14.3%, respectively, partly because of the non-recurring divestment gain. The equity ratio is at a solid level of 78.5%. Management is confident the targeted increases in full-year sales and net income will be achieved.


At Bachem, we believe that our employees make the difference. Representing our corporate culture of passion and commitment, they are the foundation of our success. We therefore strive to attract, retain, and develop highly motivated, well-qualified individuals.

View all jobs

Click here >>

Contact us


  • Please choose if you would like to receive additional email communications from Bachem:

  • Fields marked with an asterisk (*) are required

  • Hidden
  • Hidden
  • This field is for validation purposes and should be left unchanged.